Equibles does not estimate personal net worth.
Get an email with a short summary when Rocket Pharmaceuticals, Inc. publishes a filing, an earnings call transcript or a press release.
Get RCKT alertsMeg Dodge has spoken on 3 investor events across 1 company, most recently for Rocket Pharmaceuticals, Inc. on June 9, 2026. Rocket Pharmaceuticals, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Rocket Pharmaceuticals, Inc. includes Gaurav Shah (CEO and Board Member), Aaron Ondrey (CFO), Carlos Garcia-Parada (CFO) and 7 others.
“So in addition to everything that Gaurav just mentioned, Rich, I'd also say that beginning in 2025, we made the announcement when we came out with earnings from the prior year, so when we announced our 10K last year, we said that we're leaning into the cardiovascular genetic medicine company.”
“So I think the sector as a whole for gene therapy is also in a period of execution. I mean, we got earlier guidance this week from FDA.”
“Earlier, Rocket Pharmaceuticals announced that the U.S. Food and Drug Administration has granted accelerated approval to Kraslati, a gene therapy for the treatment of pediatric patients with severe leukocyte adhesion deficiency type 1.”
Transcript header (unverified)
Biotechnology · Healthcare
